Cancer cells demand excess nutrients to support their proliferation, but how tumours 26 exploit extracellular amino acids during systemic metabolic pertubations remain 27 incompletely understood. Here we use a Drosophila model of obesity-enhanced 28 tumourigenesis to uncover a systemic host-tumour nutrient circuit that supports tumour 29 growth. We demonstrate coordinate induction of systemic cachexia-like muscle wasting 30 with tumour-autonomous SLC36-family amino acid transporter expression as a proline-31 scavenging programme to drive tumourigenesis. This coordinated induction of cachexia 32 and SLC36-transporters pertains to human kidney cancer and associates with significantly 33 worse survival outcomes. We identify Indole-3-propionic acid as an optimal amino acid 34 derivative to rationally target the proline-dependency of tumour growth. Combining 35 insights from whole-animal Drosophila models and human cancer database analysis 36 provides a powerful approach towards the identification and therapeutic exploitation of 37 the amino acid vulnerabilities of tumourigenesis in the context of perturbed systemic 38 metabolic network. 39 2 Cancer cells require a constant supply of metabolic intermediates to support their proliferation. 40 To meet the biosynthetic demands associated with tumourigenesis, cancer cells actively acquire 41 nutrients from the extracellular space 1-5 . Cancer is a systemic disease that associates with a range 42 of host metabolic abnormalities such as obesity, insulin resistance, and cancer-associated 43 cachexia; each of which alter the host systemic nutritional environment. These changes in both 44 nutrient composition and availability may have profound effects on cancer development and 45 progression. However, how cancer cells sense and respond to nutritional changes in the context 46 of organismal metabolic alterations remains an under-explored area in cancer biology. 47
Cancer-associated cachexia is a systemic metabolic syndrome of weight loss associated 48 with progressive skeletal muscle wasting 6, 7 . The multifactorial and heterogeneous condition of 49 cachexia involves a complex multi-organ interplay, which has impeded its comprehensive 50 understanding at the molecular level 8 . It remains an intriguing open question in the field as to 51
whether cancer-associated cachexia is an innocent bystander, or an active metabolic programme 52 designed to meet the nutrient demands of tumourigenesis. Here we leverage a Drosophila model 53
of obesity-enhanced tumourigenesis to directly address this question in the whole-animal setting. 54 We demonstrate that obesity-enhanced tumours require proline for their growth, and that 55 tumours induce systemic muscle wasting and SLC36-family transporter expression as a 56 coordinated mechanism to exploit exogenous proline for tumourigenesis. We link these 57 mechanistic insights from our fly study with human cancer data, to rationally target the proline-58 dependency of tumours as an approach to suppress tumour growth in the context of perturbed 59 systemic metabolic network. 60
Obesity-enhanced tumours induce muscle wasting 61
We previously reported a Drosophila larval model to study the systemic effects of diet-induced 62 obesity and insulin resistance on tumour progression 9,10 . Feeding Drosophila larvae a high-63
sucrose diet (HSD) led to sugar-dependent metabolic defects including accumulation of fat, 64 systemic insulin resistance, and hyperglycemia 11 . Targeted co-activation of pathways-by expression of an oncogenic isoform of dRas1, ras1 G12V and knockout of the 66 negative regulator of Src, C-terminal src kinase (csk -/-)-in the Drosophila eye epithelia led to 67 the development of benign tumours in animals raised on a control diet (CD) (Fig. 1a ). 68
Comparatively, feeding ras1 G12V ;csk -/animals a HSD promoted aggressive tumour growth in 69 the eye epithelia ( Fig. 1b) , associated with secondary tumour formation ( Fig. 1b, arrowheads) , 70 and led to larval lethality ( Fig. 1c ). 71
To explore the interplay between diet-induced obesity, tumour progression, and systemic 72 organ wasting, we assessed the peripheral tissues of ras1 G12V ;csk -/animals-including the larval 73 fat body and body wall skeletal muscle. Fat body lipid accumulation was elevated under HSD 74 feeding, as assessed by the neutral lipid stain Nile Red (Fig. 1d, e ). Strikingly, despite possessing 75 an intact fat body, ras1 G12V ;csk -/animals raised on HSD exhibited significant skeletal muscle 76 wasting as visualised by F-actin and myosin staining ( Fig. 1f, g) . To quantify the severity of 77 muscle wasting-as assessed by imaging the fourth abdominal segment of the larval body wall 78 muscle (Extended Data Fig. 1a )-we scored animals into one of four categories: none, minor, 79 moderate or strong wasting (Extended Data Fig. 1b-e ). While most (83.33%) of the ras1 G12V ;csk -80 /animals raised on a CD displayed intact skeletal muscle, 100% of animals raised on a HSD 81 exhibited muscle wasting of some degree (Fig. 1h ). Muscle wasting was progressive; intact 82 skeletal muscle was observed at the earlier stages of larval development, and as diet-enhanced 83 tumourigenesis proceeded, skeletal muscle wasting increased (Extended Data Fig. 1f -j). 84
Functional locomotion defects-as measured by video tracking analysis 12,13 -were observed in 85 ras1 G12V ;csk -/animals raised on a HSD (Fig. 1i ). Significant defects were observed in average 86 speed, body curvature and body posture ( Fig. 1j -l). 87 3 HSD feeding in ras1 G12V ;csk -/animals led to a developmental delay in reaching the third 88 instar larval stage 9 . To rule out the possibility that observed muscle wasting was due to an 89 extended larval period, we ablated the prothoracic gland (PG)-an ecdysteroid-producing 90 organ-using the PG-specific phantom (phm)-GAL4 driver to suppress pupariation. PG-ablated 91 larvae, that were raised on a HSD and chronologically age-matched (day 6 after PG-ablation) to 92 ras1 G12V ;csk -/animals in HSD, exhibited minimal muscle wasting in a HSD (Extended Data Fig.  93 2a-c). Together these results indicate that extended larval period alone is insufficient to account 94 for the muscle wasting observed in ras1 G12V ;csk -/animals in HSD, and instead support a specific 95 role for diet-enhanced tumourigenesis in promoting muscle wasting. 96
Muscle wasting releases amino acids 97
A consequence of skeletal muscle wasting is protein degradation and subsequent release of free 98 amino acids into the circulation. We performed a genome-wide transcriptional profiling analysis 99 of dissected body-wall muscle from ras1 G12V ;csk -/animals raised on CD and HSD, from early 100 through to late stages of muscle wasting (Extended Data Fig. 3a ). As expected, Gene Set 101
Enrichment Analysis (GSEA) revealed a progressive deregulation of muscle structure 102 organisation in ras1 G12V ;csk -/animals in HSD (Extended Data Fig. 3b ). A previous report 103 demonstrated that ubiquitin-proteasome system (UPS) deregulation promotes skeletal protein 104 degradation and muscle wasting via induction of the unfolded protein response (UPR) 14 . 105
Consistent with this report, GSEA from muscle RNA-sequencing data revealed aberrant UPS 106 function (Extended Data Fig. 3c ) which correlated with accumulation of poly-ubiquitinated 107 proteins (Extended Data Fig. 3d, e ). This was coupled with an increase in UPR (Extended Data 108 Fig. 3f ), as visualised by increased perinuclear staining of the UPR-marker GRP-78 15 (Extended 109 Data Fig. 3g , h). 110
Through targeted metabolomic analysis, we measured an increase in circulating levels of 111 amino acids in the hemolymph of ras1 G12V ;csk -/animals raised on a HSD relative to CD (Fig.  112 2a and Extended Data Fig. 4a , b). Together with increased circulating 3-methylhistidine, a 113 biomarker for muscle atrophy 16 (Extended Data Fig. 4c ), these results indicate that muscle 114 protein degradation takes place in ras1 G12V ;csk -/animals raised on a HSD. Since amino acids are 115 one of the largest contributors to increased cell mass in proliferating cells 1 , our observations 116 suggested muscle wasting as a source of circulating amino acids for tumour progression. 117
Proline transporters are required for tumour growth 118
To explore candidates that could be responsible for tumour-specific amino acid utilisation, we 119 focused on amino acid transporters. Through RNA-sequencing analysis of tumour tissue from 120 ras1 G12V ;csk -/animals raised on CD and HSD, we characterised the expression profile of amino 121 acid transporters across the SLC1, SLC7, SLC36 and SLC38 families (Extended Data Fig. 5a , 122 5b). Subsequent qPCR validation confirmed that amino acid transporters of the SLC7 family 123 (minidiscs (mnd), JhI-21 and CG5535) and SLC36-family (CG8785, pathetic (path), and 124 CG1139) were upregulated in tumours of ras1 G12V ;csk -/animals raised on a HSD compared to 125 CD ( Fig. 2b ). Of note, expression levels of Slimfast (slif)-another SLC7-family member and an 126 amino acid transporter previously implicated in tumour-specific usage of amino acids 17,18 -was 127 downregulated in Ras/Src-tumours in HSD ( Fig. 2b ). 128
Reducing expression of mnd (ras1 G12V ;csk -/-,mnd RNAi ), JhI-21 (ras1 G12V ;csk -/-,JhI-21 RNAi ), 129 CG5535 (ras1 G12V ;csk -/-,CG5535 RNAi ), slif (ras1 G12V ;csk -/-,slif RNAi ) or CG8785 (ras1 G12V ;csk -/-, 130 CG8785 RNAi ), had no effect on primary tumour size ( Fig. 2c-h) . Strikingly, reducing expression 131 of path (ras1 G12V ,path RNAi ;csk -/-) or CG1139 (ras1 G12V ;csk -/-,CG1139 RNAi ) almost completely 132 suppressed diet-mediated Ras/Src-tumour growth (Fig. 2i , j and Extended Data Fig. 5c, d ). 133
Importantly, reduction in path or CG1139 levels had minimal effect on tumour growth in 134 4 ras1 G12V ;csk -/animals fed a CD indicating that neither are required for benign 135 tumour growth. Altogether, these results demonstrate that Path and CG1139 are specifically 136 required for diet-mediated enhancement of Ras/Src-tumour growth. 137
We confirmed elevation of Path and CG1139 protein levels in Ras/Src-tumours in HSD 138 using the Path-and CG1139-specific antibodies 19 (Fig. 2n, o, q, r, and Extended Data Fig. 5e, f) . 139
Path has been previously identified as one of the growth-regulatory factors under control of the 140
Hippo signalling pathway downstream transcriptional co-activator Yki 20 . Over-expression of 141
Warts (Wts)-and therefore inhibition of Yki-activity-in Ras/Src-activated cells (ras1 G12V ;csk -142 /-,wts) led to decreased Path protein but not CG1139 levels in animals fed a HSD (Fig. 2p, s ). 143
While Path was elevated specifically in Ras/Src-activated tumours in HSD ( Fig. 2n , o, and 144
Extended Data Fig. 5e ), the elevation of CG1139 was not specific to tumours but was rather 145 dependent on high sugar diet ( Fig. 2q , r, and Extended Data Fig. 5f ). Together with our previous 146 study demonstrating that diet-enhanced Ras/Src-tumours activate Yki 10 , we conclude that the 147
Hippo signalling downstream effector Yki mediates path expression in ras1 G12V ;csk -/animals 148 raised on a HSD. 149
Proline promotes tumour growth via Path 150
Mammalian SLC36-family amino acid transporters including SLC36A1 and SLC36A2 transport 151 alanine, glycine and proline 21 . Proline was the most highly increased amino acid in the 152 hemolymph of ras1 G12V ;csk -/animals in HSD ( Fig. 2a and Extended Data Fig. 4b ). Over-153 expression of Path (ras1 G12V ;csk -/-,pathA) or CG1139 (ras1 G12V ,CG1139;csk -/-) had a negligible 154 effect on tumour growth in Ras/Src-activated cells on CD, indicating that transporter expression 155 alone is insufficient to promote tumourigenesis ( Fig. 3a-c ). 156
To mimic the elevation of circulating proline levels under conditions of muscle wasting, 157
we carried out dietary supplementation of proline. Feeding animals CD supplemented with 100 158 mM L-proline had minimal effect on tumour growth of ras1 G12V ;csk -/animals in CD ( Fig. 3d ). 159
Intriguingly however, feeding proline in ras1 G12V ;csk -/-,pathA animals strongly promoted tumour 160 growth in CD ( Fig. 3e ). In striking contrast, proline feeding in ras1 G12V ,CG1139;csk -/animals 161 had no effect on tumour growth ( Fig. 3f ). Of note, feeding proline in animals with path-or 162 CG1139-overexpressing clones had minimal effect on tissue growth ( Fig. 3g -i), suggesting that 163 proline-Path mediated enhancement of tissue growth requires an oncogenic background. 164
Altogether, these results indicate that coordinated elevation of systemic proline availability and 165 tumour-autonomous transporter expression is required to promote Ras/Src-tumour growth. 166
Feeding excess L-glycine or L-alanine had minimal growth promoting effect in 167 ras1 G12V ;csk -/and ras1 G12V ;csk -/-,pathA animals ( Fig. 3j , k, m, n). Similarly, feeding the 168 biologically inert isomer of proline-D-proline-had no effect on tumour growth in both 169 ras1 G12V ;csk -/and ras1 G12V ;csk -/-,pathA animals ( Fig. 3l, o) , thereby indicating that tumour 170 response is specific to L-proline. Altogether, our data highlight the proline vulnerability of 171 obesity-enhanced Ras/Src-tumours and uncover modulation of amino acid transporter repertoire 172 as a strategy to meet the nutrient requirements of tumourigenesis. 173
Muscle wasting affects tumour growth 174
Our results suggest that cachexia-like muscle wasting and associated circulating proline 175 availability promote Ras/Src-tumourigenesis. Therefore, targeting tumour-derived factors which 176 mediate muscle wasting may not only attenuate muscle wasting but also suppress tumour growth. 177
To explore this concept, we set out to identify tumour-derived factors which mediate muscle 178
wasting. Through genome-wide transcriptional profiling analysis of dissected tumour tissue from 179 ras1 G12V ;csk -/animals raised on CD and HSD (Extended Data Fig. 5a ), we identified branchless 180 (bnl), a Drosophila fibroblast growth factor (FGF) ligand as one of the most highly upregulated 181 5 secreted factors in ras1 G12V ;csk -/tumours in animals raised on a HSD (upregulated 5.02-182 log2fold)( Fig. 4a and Extended Data Fig. 6a ). Among the three known Drosophila FGF ligands 183 (Bnl, Pyramus, and Thisbe), bnl was the only FGF ligand to be highly elevated in 184 ras1 G12V ;csk -/tumours in HSD ( Fig. 4a ). Consistently, Bnl protein expression was strongly 185 upregulated in ras1 G12V ;csk -/tumours of animals fed a HSD (Fig. 4b, c ). 186
Reducing bnl expression in Ras/Src-activated tumours (ras1 G12V ;csk -/-,bnl RNAi ) attenuated 187 muscle wasting in animals raised on a HSD (Fig. 4g -i and Extended Data Fig. 6f , k), indicating 188 that tumour-derived Bnl is required for muscle wasting. Tumour-derived factors recently 189 implicated in cachexia-like organ wasting include ImpL2 and Pvf1 22-24 . These were also elevated 190 both transcriptionally and at the protein level in ras1 G12V ;csk -/tumours in HSD (Extended Data 191 Fig. 6a-e ). However, reducing the levels of either ImpL2 (ras1 G12V ;csk -/-,ImpL2 RNAi ) or Pvf1 192 (ras1 G12V ,pvf1 RNAi ;csk -/-) failed to rescue muscle wasting as efficiently as bnl in our diet-enhanced 193
Ras/Src-tumour model (Extended Data Fig. 6g , h, k). Altogether, these results establish Bnl as a 194
functionally relevant tumour-secreted factor that contributes to muscle wasting in animals with 195 diet-enhanced Importantly, reducing bnl expression in diet-enhanced Ras/Src-tumours (ras1 G12V ;csk -/-197 ,bnl RNAi ) not only attenuated systemic muscle wasting but also suppressed tumour growth and 198 larval lethality ( Fig. 4d-f and Extended Data Fig. 6f ). Tumour autonomous Bnl and its receptor 199
Breathless (Btl) signalling has been implicated in tumourigenesis 25 . However, reducing the 200 levels of btl in Ras/Src-activated tumours (ras1 G12V ,btl RNAi ;csk -/-) had minimal effect on primary 201 tumour size or muscle wasting, indicating that tumour autonomous reduction of Bnl-Btl 202 signalling was not responsible for suppression of tumour growth in ras1 G12V ;csk -/-,bnl RNAi 203 animals (Extended Data Fig. 6i -k). Together, these results reveal that systemic muscle wasting 204 has a functional effect on tumour growth. 205 We next examined the link between proline-mediated Ras/Src tumour growth and Bnl-206 mediated muscle wasting. Feeding proline in ras1 G12V ;csk -/-,pathA animals not only promoted 207 tumour growth ( Fig. 3e ), but also led to elevated tumour expression of Bnl (Extended Data Fig.  208 7a, b) and subsequent muscle wasting (Extended Data Fig. 7c-e ). Together this demonstrates that 209
Path-dependent proline-enhancement of tumour growth promotes Bnl-mediated muscle wasting. 210
Overall, this data implicates the coordinate induction of amino acid transporter expression, 211 coupled with cachexia-like muscle wasting, as sufficient to establish a feed-forward host-tumour 212 circuit to drive tumour growth. 213
Translation to human cancer 214
To examine whether coordinated induction of cachexia and amino acid transporter expression 215 pertains to human cancers, we examined the transcriptional profile of tumour samples from 216 patients in The Cancer Genome Atlas (TCGA), across a panel of cancer types 26 . As with most 217 databases, patient data is not annotated for the presence or absence of cachexia, however an 218 earlier study adopted the expression of cachectic factors-IL-1A, IL-1B, IL-6, IL-8 and TNF-219 a-as a proxy for cachexia (Cachexia Score) 27 . In humans, the SLC36 family of amino acid 220 transporters consists of four members: SLC36A1-A4. We focused our analysis on SLC36A1 and 221 SLC36A4; the A2 and A3 isoforms were excluded due to their low tumour expression levels. 222
From the six cancer types analysed, Cachexia Score correlated positively with both SLC36A1 223 and SLC36A4 expression in kidney cancer, SLC36A1 expression in pancreatic cancer, and 224 SLC36A4 expression in liver cancer patients ( Fig. 5a-e ). To determine whether coordinated 225 induction of cachectic factors and SLC36-family transporters affected prognosis, we compared 226 survival outcomes in patient groups with high and low expression of cachectic factors and SLC36 227 transporters. Strikingly, kidney cancer patients with both a high Cachexia Score and high SLC36 228
transporter expression had significantly worse survival compared with those exhibiting both a 229 6 low Cachexia Score and low SLC36 transporter expression ( Fig. 5f, g) . Similarly patients with 230 both a high Cachexia Score and a high SLC36A1 expression in pancreatic cancer or a high 231
Cachexia Score and a high SLC36A4 expression in liver cancer exhibited worse survival rates, 232
albeit not reaching statistical significance ( Fig. 5h , i). Overall, our data demonstrates that 233 coordinated induction of cachectic factors and SLC36 transporter expression has a strong 234 negative effect on patient survival in human kidney cancer. 235
Targeting proline vulnerability of tumours 236
Taken together, our Drosophila data and human cancer database analysis specifically highlight 237 SLC36-family transporters as a target for therapeutic intervention in tumours with proline 238 vulnerability. A previous in vitro study using a human cancer cell line explored amino acid-and 239 amino acid derivative-specificities of SLC36A1 28 . By selecting competitive, non-transported 240
inhibitors of SLC36A1 from this study, we performed a whole-animal Drosophila screen to 241 identify candidates that suppress tumour growth and display minimal whole-animal toxicity. 242
Feeding ras1 G12V ;csk -/animals a HSD supplemented with 5-Hydroxy-L-tryptophan led to 243 animal lethality at the early larval stages, indicative of whole-animal toxicity. Feeding 244 ras1 G12V ;csk -/animals a HSD supplemented with either L-tryptophan or Indole-5-carboxylic 245 acid led to successful larval development, but had no inhibitory effect on tumour growth ( Figure  246 6a-c). However, feeding ras1 G12V ;csk -/animals a HSD supplemented with Indole-3-propionic 247 acid (IPA) dramatically suppressed tumour growth in HSD ( Fig. 6d ). Strikingly, 66.2% of IPA-248 fed ras1 G12V ;csk -/animals achieved pupariation in HSD, revealing significant tumour-249 suppressing efficacy coupled with minimal whole-animal toxicity ( Fig. 6g-i ). Furthermore, IPA 250 feeding had no effect on benign tumour growth in ras1 G12V ;csk -/animals raised on CD ( Fig. 6e,  251 f), supporting the notion that SLC36 inhibition only limits the growth of tumours with proline 252 vulnerability. 253 254 DISCUSSION 255
Our study reveals a systemic amino acid-utilising circuit whereby obesity-enhanced tumours 256
induce muscle wasting as a systemic metabolic network to drive tumourigenesis. A consequence 257 of muscle wasting in ras1 G12V ;csk -/animals raised on HSD was increased release of proline into 258 the circulation ( Fig. 2a ). Plasma amino acid profiling of patients with sarcopenia-a condition 259 of muscle wasting associated with aging-showed elevated plasma proline levels 29 , indicating 260 that elevated free circulating proline is a common feature of muscle wasting. We identify a 261 proline vulnerability of obesity-enhanced tumours; SLC36-family proline transporter Path is 262 required for tumour growth and exogenous proline promotes tumourigenesis through Path ( Fig.  263 2, 3). We highlight two layers of coordination in tumour metabolic response: (i) at the whole 264 organism level -by promoting cachexia-like muscle wasting and systemic amino acid 265 availability, and (ii) at the tumour-autonomous level -by altering amino acid transporter 266 repertoire ( Fig. 6j ). 267
The insights obtained from our Drosophila model were sufficient to predict altered 268 cancer patient outcomes. Human cancer database analysis demonstrates that co-expression of 269 cachectic factors alongside both SLC36A1 and SLC36A4 amino acid transporters correlates with 270 significantly worse patient survival in kidney cancer patients ( Fig. 5 ). Proline has been shown to 271 be a limiting amino acid for protein synthesis in kidney cancers 30 . Therefore, reducing proline 272 uptake with SLC36-inhibitors-as exemplified here by use of Indole-3-propionic acid (Fig. 6 To create eyeless-driven GFP-labeled clones, the MARCM system was used. Flies with the 288 genotype ey(3.5)-FLP1; act > y+ > gal4,UAS-GFP; FRT82B, tub-gal80 were crossed to flies 289 with the following genotypes: Muscle wasting quantification. Individual larvae were washed and dissected in PBS. Larval 347 body wall muscle was stained with TRITC-labelled rhodamine-phalloidin (R415; Invitrogen; 348 1:500) to visualise F-actin. Individual animals were scored into categories each representing the 349 strength of muscle wasting from either "none"; "minor"; "moderate" or "strong" (Extended Data 350 Fig. 1a-e ). Scores were assigned based on wasting of the ventral longitudinal, lateral oblique and 351 lateral longitudinal muscles centered around the 4 th abdominal segment (A4) of the larval body 352 wall (Extended Data Fig. 1a USA) in order to obtain peak information including m/z, migration time (MT), and peak area. 430
Putative metabolites were assigned from peak alignments based on the HMT metabolite database 431 on the basis of m/z and MT. Relative peak values were calculated based on internal standards 432 and normalised to sample volumes. Absolute quantification was calculated by normalising the 433 peak area of each metabolite with respect to the area of the internal standard and by using 434 standard curves, which were obtained by three-point calibrations. For hemolymph samples, 214 435 metabolites (135 metabolites in cation mode and 79 metabolites in anion mode respectively) 436
were annotated based on the HMT metabolite database, including 3-methylhistidine and proline. 437 438
Human cancer database analyses. Transformed tissue is labelled with GFP (green). Secondary tumours are observed in a subset of animals (arrowheads in b). a', b', Matching dissected eye epithelial tissue stained with DAPI (red). Scale bar, 250 µm. c, Pupariation percentage of ras1 G12V ;csk -/animals raised on CD or HSD. Results are shown as mean ± SEM of four independent experiments with n³10 animals for each data point. Asterisks indicate statistically significant difference (***; p<0.005). d, e, Nile Red (red) and DAPI (blue) staining of dissected fat body tissue from ras1 G12V ;csk -/third-instar larvae fed a CD (d) or HSD (e). Scale bar, 100 µm. f, g, F-actin (red) and anti-myosin (green) staining of dissected larval body wall muscle tissue from ras1 G12V ;csk -/third-instar larvae fed a CD (f) or HSD (g). Scale bar, 100 µm. h, Matching body wall muscle wasting quantification. n³30 per condition. i, Individual larval trajectories from video tracking analysis of ras1 G12V ;csk -/third-instar larvae fed a CD, or HSD. Scale bar, 1 cm. j-l, Average midbody speed (j), body curvature (k), and body posture (l) of ras1 G12V ;csk -/thirdinstar larvae fed a CD, or HSD with results shown as mean ± SEM with each data point representing one individual animal. Asterisks indicate statistically significant difference (***; p<0.005, **; 0.005<p<0.025). Figure 2 . Drosophila SLC36-family amino acid transporters Path and CG1139 are required for obesity-enhanced Ras/Src tumour growth. a, Circulating hemolymph levels of upregulated amino acids in ras1 G12V ;csk -/animals raised on HSD compared to ras1 G12V ;csk -/animals raised on CD. Results are shown as mean relative fold change from ras1 G12V ;csk -/animals raised on HSD vs. CD. b, Relative log2fold change of SLC7 and SLC36 family amino acid transporters in dissected tumour tissue from ras1 G12V ;csk -/animals raised on HSD compared to ras1 G12V ;csk -/animals raised on CD, as determined by qPCR. Samples are normalised to Act88F. Results are shown as mean ± SEM. c-j, Dissected eye epithelial tissue stained with DAPI (red) from ras1 G12V ;csk -/animals raised on HSD (c), with mnd RNAi (d), JhI-21 RNAi (e), CG5535 RNAi (f), slif RNAi (g), CG8785 RNAi (h), path RNAi (i), and CG1139 RNAi (j). Scale bar, 250 µm. k-m, Dissected eye epithelial tissue stained with DAPI (red) from ras1 G12V ;csk -/animals raised on CD (k), with path RNAi (l), and CG1139 RNAi (m). Scale bar, 250 µm. n-p, Anti-Path staining (red) of dissected tumour tissue from ras1 G12V ;csk -/animals raised on CD (n), ras1 G12V ;csk -/animals raised on HSD (o), and ras1 G12V ;csk -/-,wts animals raised on HSD (p) with DAPI (blue). Scale bar, 100 µm. q-s, Anti-CG1139 staining (red) of dissected tumour tissue from ras1 G12V ;csk -/animals raised on CD (q), ras1 G12V ;csk -/animals raised on HSD (r), and ras1 G12V ;csk -/-,wts animals raised on HSD (s) with DAPI (blue). Scale bar, 100 µm. Muscle wasting scores increase in strength from left to right: "no wasting" (b), "minor" (c), "moderate" (d) and "strong" (e). Scale bar, 100 µm. f-i, Dissected larval body wall muscle of ras1 G12V ;csk -/animals raised on CD (f) or on HSD at Early (g), Mid (h) and Late stage (i) Scale bar, 100 µm. j, Matching body wall muscle wasting quantification of ras1 G12V ;csk -/animals raised on CD and HSD. X-axis represents the percentage of individual animals scoring in each category denoted "none", "mild", "moderate" or "strong". n³30 per condition. a, Third instar larvae of ras1 G12V ;csk -/and phm>grim, tub-gal80 ts animals raised on HSD for 12 days in 18°C plus 2, 4 and 6 days after temperature shift to 29°C (+2d, +4d and +6d respectively). ras1 G12V ;csk -/animals are imaged under BF and GFP. phm>grim animals (tumour-free) are imaged under BF. b, Matching dissected larval body wall muscle. Scale bar, 100 µm. c, Matching body wall muscle wasting quantification. n³30 per condition. Figure 3 . HSD-fed Ras/Src-animals promote muscle wasting via proteasome dysfunction and unfolded protein response. a, Principal Component Analysis of dissected muscle RNA-sequencing data from ras1 G12V ;csk -/animals raised on CD (blue) and ras1 G12V ;csk -/animals raised on HSD at Early (pink), Mid (red) and Late Stage (brown). n=4 per condition. b, Gene Set Enrichment Analysis (GSEA) for the functional category 'Muscle Structure & Organisation' from dissected muscle RNA-sequencing data from ras1 G12V ;csk -/animals raised on HSD at Early Stage (Early), Mid Stage (Mid) and Late Stage (Late) compared to ras1 G12V ;csk -/animals raised on CD. Data is displayed as cumulative enrichment score over the time course. Gene sets in purple are derived from Hallmark (H) datasets, gene sets in green are derived from Curated (C2) datasets and gene sets in pink are derived from Gene Ontology (C5) datasets. c, GSEA (as for b) for the functional category 'Ubiquitin Proteasome System'. d, e, Poly-Ubiquitin staining (green) of dissected body wall muscle from ras1 G12V ;csk -/animals raised on CD (d) or HSD (e) and with DAPI (blue) and F-actin (red). Scale bar, 100 µm. f, GSEA (as for b) for the functional category 'Unfolded Protein Response'. g, h, GRP-78 staining (green) of dissected body wall muscle from ras1 G12V ;csk -/animals raised on CD (g) or HSD (h) and with DAPI (blue) and F-actin (red). Scale bar, 100 µm. 
